Clinical trial
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced…
NCT00091078 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00091078 |
|---|---|
| Title | Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery |
| Official title | A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 96 |
| Start date | Sep 1, 2005 |
| Primary completion | Jul 1, 2006 |
| First posted | Sep 8, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: